Literature DB >> 16624484

Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells.

Radosław Januchowski1, Mikołaj Dabrowski, Harold Ofori, Paweł P Jagodzinski.   

Abstract

Histone deacetylase inhibitor Trichostatin A (TSA), alone, is able to activate the transcription of DNA methylation-mediated silenced genes in human cancer cells. Increase in expression and half-life of the DNA methyltransferase DNMT1 has been found in carcinomas of the colon, lung, liver, prostate, and breast cancer. This overexpression of DNMT1 is responsible for hypermethylation of regulatory sequences of many genes involved in tumorigenesis. Using quantitative real-time PCR and Western blot analysis, we found that TSA down-regulate DNMT1 mRNA and protein expression in Jurkat T leukemia cells clone E6-1. We also observed that TSA decreased DNMT1 mRNA stability and reduced this transcript half-life from approximately 7 to 2h. We also found that protein biosynthesis is needed for posttranscriptional regulation of DNMT1 mRNA, which suggests the involvement of an RNase and/or mRNA stabilization protein entity in DNMT1 transcript stabilization. Our findings suggest that TSA not only alters histone acetylation, but also may affect DNA methylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16624484     DOI: 10.1016/j.canlet.2006.03.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Histone/protein deacetylases and T-cell immune responses.

Authors:  Tatiana Akimova; Ulf H Beier; Yujie Liu; Liqing Wang; Wayne W Hancock
Journal:  Blood       Date:  2012-01-12       Impact factor: 22.113

Review 2.  Epigenetic control of embryo-uterine crosstalk at peri-implantation.

Authors:  Shuangbo Kong; Chan Zhou; Haili Bao; Zhangli Ni; Mengying Liu; Bo He; Lin Huang; Yang Sun; Haibin Wang; Jinhua Lu
Journal:  Cell Mol Life Sci       Date:  2019-07-27       Impact factor: 9.261

3.  Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle.

Authors:  Derek Daigle; Lyn Gradoville; David Tuck; Vince Schulz; Ruth Wang'ondu; Jianjiang Ye; Kelly Gorres; George Miller
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

4.  Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics.

Authors:  Mohsen Karimi Arzenani; Atosa Esteki Zade; Yu Ming; Susanne J H Vijverberg; Zhe Zhang; Zahidul Khan; Syed Sadique; Lorenz Kallenbach; LiFu Hu; Vladana Vukojević; Tomas J Ekström
Journal:  Mol Cell Biol       Date:  2011-07-26       Impact factor: 4.272

Review 5.  Nonhistone protein acetylation as cancer therapy targets.

Authors:  Brahma N Singh; Guanghua Zhang; Yi L Hwa; Jinping Li; Sean C Dowdy; Shi-Wen Jiang
Journal:  Expert Rev Anticancer Ther       Date:  2010-06       Impact factor: 4.512

6.  Effects of trichostatin A on neuronal mu-opioid receptor gene expression.

Authors:  Ying-Chih Lin; Kelly E Flock; Ryan J Cook; Amanda J Hunkele; Horace H Loh; Jane L Ko
Journal:  Brain Res       Date:  2008-10-11       Impact factor: 3.252

7.  Epigenetic regulation of a murine retrotransposon by a dual histone modification mark.

Authors:  Reinhard Brunmeir; Sabine Lagger; Elisabeth Simboeck; Anna Sawicka; Gerda Egger; Astrid Hagelkruys; Yu Zhang; Patrick Matthias; Wolfgang J Miller; Christian Seiser
Journal:  PLoS Genet       Date:  2010-04-29       Impact factor: 5.917

8.  Functional analysis and identification of cis-regulatory elements of human chromosome 21 gene promoters.

Authors:  Hans-Jörg Warnatz; Robert Querfurth; Anna Guerasimova; Xi Cheng; Stefan A Haas; Andrew L Hufton; Thomas Manke; Dominique Vanhecke; Wilfried Nietfeld; Martin Vingron; Michal Janitz; Hans Lehrach; Marie-Laure Yaspo
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

9.  Effects of histone deacetylase inhibitor oxamflatin on in vitro porcine somatic cell nuclear transfer embryos.

Authors:  Liming Hou; Fanhua Ma; Jinzeng Yang; Hasan Riaz; Yongliang Wang; Wangjun Wu; Xiaoliang Xia; Zhiyuan Ma; Ying Zhou; Lin Zhang; Wenqin Ying; Dequan Xu; Bo Zuo; Zhuqing Ren; Yuanzhu Xiong
Journal:  Cell Reprogram       Date:  2014-06-24       Impact factor: 1.987

10.  Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.

Authors:  Warren Fiskus; Kate Buckley; Rekha Rao; Aditya Mandawat; Yonghua Yang; Rajeshree Joshi; Yongchao Wang; Ramesh Balusu; Jianguang Chen; Sanjay Koul; Atul Joshi; Sunil Upadhyay; Peter Atadja; Kapil N Bhalla
Journal:  Cancer Biol Ther       Date:  2009-05-18       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.